AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$TPST

Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903 Secured access to additional ca

Event · Earnings
Original reporting
SEC EDGAR 8-K
Published Nov 13, 2026, 10:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TPST
Bearish
high confidence
Mentioned
$TPST
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TPSTBearishMed
01

Why it matters

The Q3 results and financing indicate short‑term liquidity strain but also strategic progress with a new BCMA/GPRC5D candidate and a partnership with Senlang.

02

Market read

First‑report 8‑K with fresh earnings, cash burn, and capital raise; likely prompts short‑term price decline but underscores strategic milestones.

03

What to watch

Potential non‑dilutive funding from partnerships or future licensing deals not yet disclosed.

Relevance 7/10Novelty 6/10Timing: after-hours filing

Background

Tempest Therapeutics is a clinical‑stage biotech focused on in‑vivo CAR‑T platforms targeting cancer and autoimmune diseases.

Company-level read

Ticker impact

$TPSTBearishHigh confidence
Context

Tempest Therapeutics filed its Q3 2026 results, disclosed a $2.5M private placement, a $50M equity line of credit and highlighted a going‑concern risk.

Expected impact

likely pressure as investors price in cash shortage and dilution

Evidence & confidence

First‑report 8‑K with fresh financials and capital raise; market typically reacts negatively to going‑concern disclosures.

Market effects

Sector

Highlights financing challenges for early‑stage biotech firms developing in‑vivo CAR‑T therapies.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche CAR‑T sector.

Counterpoint

What could challenge this read

The exclusive Senlang license could unlock significant value if clinical data materializes, offering a turnaround catalyst.

Key entities

  • company
    Tempest Therapeutics, Inc.

    Biotech issuer of ticker TPST.

  • partner
    Hebei Senlang Biotechnology Co., Ltd.

    Provider of the exclusive CD7‑targeted lentiviral vector platform.

  • financier
    Lincoln Park Capital Fund, LLC

    Provider of the equity line of credit and purchaser of shares.

Read at source← All news

Related articles

$TPSTMedAI 8/10

Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead…

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate -Tempest secures exclusive global rights outside China to a targeted lentiviral platform and po

SEC EDGAR 8-K
$TPSTHigh

Tempest Therapeutics stock surges on Senlang CAR-T deal

Tempest Therapeutics (NASDAQ:TPST) shares rose 21% after announcing an exclusive option agreement with Hebei Senlang Biotechnology to license Senlang’s CD7-targeted lentiviral vector platform, including a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple myeloma. The deal complements Tempest’s existing in vivo CAR-T platform, set to enter clinical trials later this year.

investing.com
$TPSTMed

Tempest Q2 Loss Narrows; Advances In Vivo CAR-T Pipeline With TPST-4003

Tempest Therapeutics (TPST) reported Q2 2026 net loss of $5.2M, or $0.34/share, versus $7.9M, or $2.07/share a year earlier. R&D fell to $1.8M and G&A to $3.4M. Cash was $0.8M at June 30. The company advanced TPST-4003 (CD19/BCMA via CD7 mRNA/LNP) with a Senlang collaboration and a China investigator trial starting Q4 2026, and cited interim TPST-2003 data. Shares were up in premarket.

rttnews.com
$TPSTMed

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T,

SEC EDGAR 8-K